Skip to main content
. Author manuscript; available in PMC: 2015 Mar 1.
Published in final edited form as: Pancreas. 2014 Mar;43(2):298–305. doi: 10.1097/MPA.0000000000000099

FIGURE 1.

FIGURE 1

Degree of tumor growth inhibition (TGI) of patient pancreatic tumors engrafted subcutaneously in SCID mice achieved by Apo2L/TRAIL treatment for 3 sensitive and 3 resistant xenografts. Tumor bearing mice were treated with 500µg/dose of Apo2L/TRAIL daily for approximately two 2-week cycles, separated by 1 week rest (the day on which the % tumor growth inhibition was calculated varied slightly between experiments as indicated). Sensitivity was designated based on the results of the Student t-test comparing average tumor size on day indicated (**p<0.005; *p<0.05). Gray bars- sensitive tumors; black bars- resistant tumors.